TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Research on Nicorandil Treatment of Patients Diagnosed as CHD (Coronary Heart Disease) With Stable Angina

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject must be diagnosed as stable CHD, and must have at least one of these histories:~  1. A history of coronary revascularization Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Surgery at least 3 months ago~ 2. Myocardial infarction~ 3. More than 50 percent (%) stenosis detected by angiography~ 4. Exercise Tolerance Testing (ETT) or Computed Tomography Angiography (CTA) showed more than 50% stenosis with typical angina symptoms~* Subjects must have at least 2 times of typical symptoms of myocardial ischemia occurred within a week Other protocol defined inclusion criteria could apply~Exclusion Criteria:~* Coronary syndrome or considering acute coronary syndrome (ACS)~* Left main coronary artery disease without revascularization~* Aortic stenosis~* Obstructive hypertrophic cardiomyopathy~* Subjects with hypertension systolic blood pressure (SBP) greater than (\>) 170 millimeters of mercury (mmHg) or diastolic blood pressure (DBP) \>100 mmHg) or hypotension (SBP less than \[\<\] 90 mmHg or DBP\<60 mmHg)~* Diagnosis as postural hypotension before~* Congestive heart failure (New York Heart Association \[NYHA\] class III - IV~* Ejection fraction (EF)\<40% by Echocardiography~* Arrhythmias requiring active treatment~* Gastro-intestinal ulcer~* Concomitant medication such as Sulphonyl urea, PDE-5 inhibitor such as sildenafil, Trimetazidine for treatment of angina pectoris Other protocol defined exclusion criteria could apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard treatment plus nicorandil (Type: EXPERIMENTAL): The subjects will receive nicorandil 5 milligram (mg ) tablet orally three times daily for a period of 12 weeks along with one of the standard antianginal therapies (such as aspirin, beta-blockers, lipid lowering statins and angiotensin-converting enzyme inhibitors \[(ACEIs\] as permitted by disease condition /as per standard local practices/prescribed per discretion of investigators).
- Standard treatment (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of rheumatoid arthritis (RA) for ≥ 3 months based on the 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification criteria for RA~* Participant meets the following minimum disease activity criteria:~  * ≥ 6 swollen joints (based on 66 joint counts) and ≥ 6 tender joints (based on 68 joint counts) at Screening and Baseline Visits~ * High-sensitivity C-reactive protein (hsCRP) ≥ 3 mg/L (central lab) at Screening Visit~* Participants must have been treated for ≥ 3 months with ≥ 1 biologic disease-modifying anti-rheumatic drug (bDMARD) therapy but continue to exhibit active RA or had to discontinue due to intolerability or toxicity, irrespective of treatment duration~* Participants must have been receiving conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) therapy ≥ 3 months and on a stable dose for ≥ 4 weeks prior to the first dose of study drug~* Participants must have discontinued all bDMARDs prior to the first dose of study drug~Exclusion Criteria:~- Participant has prior exposure to any Janus Kinase (JAK) inhibitor for greater than 2 weeks (including but not limited to upadacitinib, tofacitinib, baricitinib, and filgotinib). A washout period of ≥ 30 days is required for any JAK inhibitor prior to the first dose of study drug.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ELS placebo/UPA placebo (Type: PLACEBO_COMPARATOR): Placebo capsule for elsubrutinib once a day by mouth for 12 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 12 weeks
- UPA 15 mg/ELS 60 mg (Type: EXPERIMENTAL): 15 mg film-coated upadacitinib tablet once a day by mouth for 12 weeks; 60 mg elsubrutinib capsule once a day by mouth for 12 weeks
- ELS 60 mg/UPA placebo (Type: EXPERIMENTAL): 60 mg elsubrutinib capsule once a day by mouth for 12 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 12 weeks
- ELS 20 mg/UPA placebo (Type: EXPERIMENTAL): 20 mg elsubrutinib capsule once a day by mouth for 12 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 12 weeks
- ELS 5 mg/UPA placebo (Type: EXPERIMENTAL): 5 mg elsubrutinib capsule once a day by mouth for 12 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 12 weeks
- UPA 15 mg/ELS placebo (Type: EXPERIMENTAL): 15 mg film-coated upadacitinib tablet once a day by mouth for 12 weeks; placebo capsule for elsubrutinib once a day by mouth for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability of Ziprasidone in Children and Adolescents With Bipolar I Disorder (Manic or Mixed)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participation in double-blind treatment study A1281132, meeting specific criteria of duration and safety~Exclusion Criteria:~* Imminent risk of suicide or homicide, as judged by the site investigator;serious adverse event related to study medication in study A1281132; significant prolongation of QT interval in study A1281132.

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Open (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase I Trial of HIV-1 C4-V3 Polyvalent Peptide Vaccine in HIV-1 Infected Persons

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria~Concurrent Medication:~Allowed:~* Other medically indicated vaccinations, provided they are administered at least 2 weeks before or after any study injection.~* Alcohol use limited to 1 oz per day of 100 proof.~Patients must have:~* HIV infection without evidence of AIDS.~* CD4 count \> 500 cells/mm3.~Exclusion Criteria~Co-existing Condition:~Patients with the following symptoms or conditions are excluded:~* Current evidence of underlying lung or liver disease.~* Suspected or diagnosed allergy to any vaccine component.~* Medical contraindication to protocol participation.~* Undergoing allergy skin testing or desensitization.~Concurrent Medication:~Excluded:~* Antiretroviral therapy (unless clinically indicated and with approval of investigator).~* Immunosuppressive or immunomodulatory therapy.~* Nonsteroidal anti-inflammatory agents (except short-term therapy for acute conditions).~* Drugs with known hepatotoxicity.~* Alcohol intake \> 1 oz per day of 100 proof.~Patients with the following prior conditions are excluded:~* History of underlying lung disease.~* Abnormal chest radiograph within 2 weeks prior to first vaccine injection.~* History of underlying liver disease.~* Abnormal hepatitis B surface antigen or hepatitis C antibody test within 2 weeks prior to first vaccine injection.~* Abnormal liver function tests within 30 days prior to study entry.~* Evidence of uveitis by slit lamp exam within 2 weeks prior to study entry.~* Anergic as evidenced by negative skin test responses to all three antigens in a panel consisting of tetanus toxoid, mumps, and Candida albicans, within 6 weeks prior to first vaccine injection.~* Prior participation on an HIV vaccine trial.~Prior Medication:~Excluded within the past 3 months:~* Antiretroviral therapy.~* Immunosuppressive drugs.~* Alpha interferon or any immunomodulatory drugs.~* Any investigational HIV drugs or therapies. Current alcohol abuse.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Platelet Rich Plasma on Healing of Operated Pilonidal Sinus by Open Method

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient age \>18 years and \<45 years.~2. All patient who underwent sacrococcygeal pilonidal sinus operation (Open method).~Exclusion Criteria:~1. Pilonidal abscess.~2. Diabetic patient.~3. HGB \< 10 g/dl.~4. Platelet count \< 105/ul.~5. Anticoagulant treatment.~6. Wound cavity \>35cc.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Group A (Type: NO_INTERVENTION): 50 Participants who underwent a total excision of the pilonidal sinus and the wound remained open for secondary healing.
- Group B (Type: ACTIVE_COMPARATOR): 50 Participants who underwent the same operation with secondary healing intention but on postoperative days 4 and 12 the platelet rich plasma was injected to the surgical wound.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dose-range-finding, Phase 2 Trial of Oral Linaclotide Acetate Administered to Patients With Chronic Constipation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is 18 years of age or older~* Patient meets colonoscopy requirements according to the American Gastroenterological Association~* Patient meets criteria for chronic constipation including weekly bowel movement frequency requirements and reports one or more symptoms of constipation according to protocol requirements~* Patient has successfully completed study requirements with no clinically-significant findings: physical exam, ECG, clinical laboratory tests~* Patient is fluent in English~Exclusion Criteria:~* Patient reports loose or watery stools~* Patient meets criteria for IBS including protocol-defined abdominal discomfort or pain~* Patient may not take prohibited medications per protocol~* Medical diagnoses, medical conditions, or family history that would not make the patient a good candidate for the study or limit the patient's ability to complete the clinical study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 72 ug linaclotide acetate (Type: ACTIVE_COMPARATOR): None
- 145 ug linaclotide acetate (Type: ACTIVE_COMPARATOR): None
- 290 ug linaclotide acetate (Type: ACTIVE_COMPARATOR): None
- 579 ug linaclotide acetate (Type: ACTIVE_COMPARATOR): None
- Matching Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: S0312, Gemcitabine and Capecitabine in Treating Patients With Advanced Renal Cell (Kidney) Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed renal cell carcinoma~  * Metastatic (M1) disease OR~ * M0 provided the primary tumor is unresectable~* Measurable disease~  * At least 1 unidimensionally measurable lesion~ * Soft tissue disease that has been irradiated within the past 2 months is not considered measurable disease~ * Soft tissue disease within a prior radiation field is measurable provided it has progressed since therapy and there is also measurable disease outside of the irradiated field~* No prior or concurrent brain metastases~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* Zubrod 0-2~Life expectancy~* Not specified~Hematopoietic~* Absolute granulocyte count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic~* Bilirubin no greater than 1.5 times upper limit of normal (ULN)~* Aspartate aminotransferase (SGOT) no greater than 1.5 times ULN~Renal~* Creatinine clearance at least 50 mL/min~Cardiovascular~* No symptomatic congestive heart failure~* No unstable angina pectoris~* No cardiac arrhythmia~Other~* Not pregnant or nursing~* Fertile patients must use effective contraception~* No other concurrent uncontrolled illness that would preclude study participation~* No psychiatric illness or social situation that would preclude study compliance~* No uncontrolled diabetes mellitus~* No ongoing or active infection~* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or stage I or II cancer currently in complete remission~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No more than 2 prior immunotherapy regimens comprising interferon (IFN) and/or interleukin-2 (IL-2)~* At least 28 days since prior IFN or IL-2 and recovered~Chemotherapy~* No prior chemotherapy for renal cell cancer~Endocrine therapy~* Not specified~Radiotherapy~* See Disease Characteristics~* No prior radiotherapy to 25% or more of the bone marrow~* At least 21 days since prior radiotherapy and recovered~Surgery~* At least 28 days since prior surgery and recovered~* Prior resection of the primary tumor allowed (in patients with metastatic disease)~Other~* At least 4 weeks since prior sorivudine or brivudine~* No concurrent sorivudine or chemically related analogues (e.g., brivudine)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): Gemcitabine + Capecitabine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Efficacy and Safety of Upadacitinib in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of CD for at least 3 months prior to Baseline.~* Confirmed diagnosis of moderate to severe CD as assessed by stool frequency (SF), abdominal pain (AP) score.~* Evidence of mucosal inflammation based on the Simplified Endoscopic Score for Crohn's disease (SES-CD) on an endoscopy confirmed by a central reader.~* Demonstrated an inadequate response or intolerance to one or more conventional and/or biologic therapies (oral locally acting steroids, intravenous or oral corticosteroids, immunosuppressants or biologic therapies for CD), in the opinion of the investigator.~  * Note: Participants who have had inadequate response or intolerance to conventional therapy who have received prior biologic may be enrolled; however, participants must have discontinued the biologic for reasons other than inadequate response or intolerance (e.g., change of insurance, well controlled disease).~* If female, participant must meet the contraception recommendations.~Exclusion Criteria:~* Participant with a current diagnosis of ulcerative colitis or indeterminate colitis.~* Participant not on stable doses of CD related antibiotics, oral aminosalicylates, corticosteroids or methotrexate (MTX).~* Participant with the following ongoing known complications of CD: abscess (abdominal or peri-anal), symptomatic bowel strictures, fulminant colitis, toxic megacolon, \> 2 entire missing segments of the following 5 segments: terminal ileum, right colon, transverse colon, sigmoid and left colon, and rectum, or any other manifestation that might require surgery while enrolled in the study.~* Participant with ostomy or ileoanal pouch.~* Participant diagnosed with conditions that could interfere with drug absorption including but not limited to short gut or short bowel syndrome.~* Screening laboratory and other analyses show abnormal results.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive placebo once daily for 12 weeks in Part 1. Clinical non-responders will receive 45 mg upadacitinib once daily for 12 weeks in Part 2.
- Upadacitinib (Type: EXPERIMENTAL): Participants will receive 45 mg upadacitinib once daily for 12 weeks in Part 1. Clinical non-responders will receive 30 mg upadacitinib once daily for 12 weeks in Part 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 18F Fluciclovine (FACBC) PET/CT in Patients With Rising PSA After Initial Prostate Cancer Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* History of histologically confirmed adenocarcinoma of the prostate post curative-intent local treatment (radical prostatectomy, local radiotherapy, brachytherapy).~* Suspicion of recurrent prostate carcinoma after previous presumed definitive therapy for organ confined disease defined as :~* Post prostatectomy: Detectable or rising PSA level that is \>0.2 ng/mL with a second confirmatory level of \>0.2 ng/mL~* Post non-prostatectomy: PSA rise ≥ 2ng/mL over nadir~* Negative or equivocal findings on standard-of-care imaging for restaging of disease in the previous 60 days consisting of: Whole-body 99mTc bone scintigraphy or NaF PET-CT; and either CT or MRI of the pelvis (or the abdomen and pelvis).~* Being considered for salvage therapy~* Any non-surgical local treatment such as previous cryotherapy, external beam radiation, or HiFU (Ultrasound) must have occurred at least 1 year in the past.~* Previous brachytherapy treatment will have occurred at least 2 years in the past~* Ability to understand and the willingness to sign a written informed consent.~Exclusion Criteria:~* Ongoing treatment with any systemic therapy intended for the treatment of prostate cancer (e.g., antiandrogen or LHRH agonist or antagonist)~* Androgen deprivation therapy (ADT) in the past 3 months~* History of bilateral orchidectomy~* Inability to tolerate 18F-fluciclovine PET/CT

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 18F-fluciclovine PET CT (Type: EXPERIMENTAL): Single intravenous administration of 18F-fluciclovine PET CT.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cough and Swallow Rehab Following Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Acute (0-14 days) and subacute (14 days - 6 months) ischemic stroke~2. Neurologic status permits participation.~3. Medical status permits participation.~Exclusion Criteria:~1. Dysphagia secondary to something other than stroke.~2. Refuses consent.~3. Incapable of informed consent and has no representative.~4. Multiple strokes and previous history of dysphagia secondary to stroke.~5. Longer than 6 months post-stroke~6. Known cardiac valve thrombosis~7. Stroke etiology of dissection~8. Unstable / evolving stroke lesion.~9. History of cancer in the head or neck~10. History of radiation to the head or neck~11. History of degenerative disease

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Expiratory muscle strength training (EMST) (Type: EXPERIMENTAL): Participants will complete 5 weeks of EMST training, 5 repetitions per set, 5 sets per day, 5 days per week.
- Placebo expiratory training (Type: PLACEBO_COMPARATOR): Same look and feel of EMST with no resistance. Same protocol - 5 repetitions of 5 sets, 5 days per week

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Glivec in Pediatric Chronic Myeloid Leukemia (CML)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Old \< 18 years, male or female.~* Chronic myeloid leukaemia confirmed on the cytogenetic level by the presence of the translocation t(9; 22) (q34; q11) or by the presence of transcript BCR-ABL in the event of absence of description of the translocation t(9; 22) (q34; q11).~* Chronic phase of a chronic myeloid leukaemia~* Absence of extra-medullary disease (except for a hepatomegaly and/or of a splenomegaly).~* Absence of any former treatment of chronic myeloid leukaemia except for hydroxyurea.~* Stop of hydroxyurea at least week before the beginning of the imatinib mesylate.~* Diagnosis of chronic myeloid leukaemia in chronic phase recent (less than 2 months).~* Score of Lansky ≥ 60.~* Effective contraception among patients in age to procreate.~* Written voluntary informed consent of the two parents or the legal guardian.~Exclusion Criteria:~* Patients with grade 3 / 4 cardiac disease.~* Pathology cardiac, pulmonary, hepatic, renal or neurological of grade \> 2 (WHO).~* Participation in a clinical trial in the 28 days preceding the beginning by the treatment.~* Impossible Follow-up during at least 2 years, patient not compliant.~* Expectant mother or nursing.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Imatinib (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete